A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 25 Apr 2025
At a glance
- Drugs Carboplatin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Jun 2024 Results (n=275),presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 06 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Jan 2026.
- 06 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Jan 2026.